Industry: Healthcare Region: United States Transaction Price: USD 1 million Transaction Method: Equity investment
Project Introduction:
A clinical-stage medical technology company founded at Stanford University with the vision of preventing glaucoma blindness has developed non-invasive diagnostics and devices for drug delivery, monitoring eye pressure, and delivering the right drug at the right dose at the right time, which can provide personalized treatment to patients, improve efficacy and reduce side effects.
So far, the company has had promising results in ongoing clinical trials, and its first product should be approved by the U.S. Food and Drug Administration (FDA) by the end of 2022.
Project Features:
There are special opportunities to intervene and prevent glaucomato-related blindness, and to significantly improve the way doctors treat the disease, manage it in novel, non-invasive and easy-to-use ways, and design and manufacture devices with large market potential for remote patient diagnosis and intelligent drug delivery.
Market Opportunities:
A rapidly growing $20 billion market. Three million people in the United States, 80 million worldwide, hundreds of millions of people are at risk. Glaucoma is the leading cause of irreversible blindness.
Project Advantages:
Experienced team, strong, secure intellectual property, ready product, significant impact, high returns.
Way of cooperation:
$10 million in Series A funding
Purpose of Funds:
Complete clinical trials, apply for FDA approval, intellectual property application.